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Arteriovenous fistulae (AVF) are the most common access created for 
hemodialysis, but up to 60% do not sustain dialysis within a year, suggesting a need to 
improve AVF maturation and patency. In a mouse AVF model, Akt1 regulates fistula wall 
thickness and diameter. We hypothesized that inhibition of the Akt1-mTORC1 axis alters 
venous remodeling to improve AVF patency. Daily intraperitoneal injections of 
rapamycin reduced AVF wall thickness with no change in diameter. Rapamycin 
decreased smooth muscle cell (SMC) and macrophage proliferation; rapamycin also 
reduced both M1 and M2 type macrophages. AVF in mice treated with rapamycin had 
reduced Akt1 and mTORC1 but not mTORC2 phosphorylation. Depletion of 
macrophages with clodronate-containing liposomes was also associated with reduced 
AVF wall thickness and both M1- and M2-type macrophages; however, AVF patency was 
reduced. Rapamycin was associated with improved long-term patency, enhanced early 
AVF remodeling and sustained reduction of SMC proliferation. These results suggest 
that rapamycin improves AVF patency by reducing early inflammation and wall 
thickening while attenuating the Akt1-mTORC1 signaling pathway in SMC and 
macrophages. Macrophages are associated with AVF wall thickening and M2-type 
macrophages may play a mechanistic role in AVF maturation. Rapamycin is a potential 
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1.1 Poor Clinical Outcomes in Arteriovenous Fistulae Utilization 
Veins are frequently exposed to arterial environment by surgeons when creating 
arteriovenous fistulae (AVF) for hemodialysis access in end-stage renal disease (ESRD). 
With over half a million people affected by ESRD in the United States and a mortality of 
approximately 88,000 people each year, the incidence of ESRD requiring therapy is over 
100,000 new cases a year.1 An AVF, which joins a vein directly to the artery is the 
preferred mode of hemodialysis access with demonstrated superior long-term results 
compared to prosthetic grafts and catheter access.2 Despite the known superiority, AVF 
are still far from perfect; they must mature, e.g. dilate, thicken and increase flow prior 
to use. However AVF can fail to mature in ~30% of cases3 and even if matured correctly, 
primary AVF failure occurs in ~35-40% in just the first year.4 These poor clinical results of 
AVF reflect our imperfect understanding of how the vein adapts to the arterial 
environment and clearly shows that our knowledge gap creates an unmet medical need 
for novel approaches to enhance venous adaptation.4-6 The Society of Vascular Surgery 
recently published enhancing AVF maturation and durability as one of its highest and 
most critical clinical research priorities.7 
 
1.2. Mechanisms of Fistula Maturation and Failure 
Following AVF creation, the vein is exposed to a high flow and shear stress, low 
pressure arterial environment, leading to “maturation” of both the arterial inflow and 




for a successful dialysis session. Adaptation of the vein to the increased flow and shear 
stress requires dilation and outward remodeling of the venous wall. This process is 
accomplished by a delicate balance of extracellular matrix (ECM) remodeling, 
inflammation, growth factor secretion, and cell adhesion molecule upregulation in all 
three layers of the venous wall.8-11  
During fistula maturation, the ECM of the venous limb exhibits changes as an 
adaptive response to the “arterialized” environment.12 These changes can be 
categorized in to three temporal phases; early phase (breakdown), transition phase 
(reorganize) and late phase (rebuild). The early phase is characterized by an increased 
ratio of matrix metalloproteinase (MMP) to tissue inhibitor of metalloproteinase (TIMP), 
which results in degradation of collagen and elastin scaffolds, allowing for easier cell 
migration during the transition and late phases. Reorganization of scaffolds and 
rebuilding of the ECM with larger non-collagenous and glycoproteins such as fibronectin 
occur after the breakdown phase to allow for complete fistula maturation.13 
While ECM degradation is regulated by MMP, its deposition is modulated by 
transforming growth factor-β (TGF-β).14 Diverse cell types in the venous wall, such as 
endothelial cells (EC), smooth muscle cells (SMC), and inflammatory cells produce TGF-β 
and its expression is upregulated during both early and late phases of AVF maturation. 
While local inflammation of the vessel wall is necessary for successful fistula maturation, 
elevated systemic inflammatory markers predict fistula failure.9,15 Locally, macrophages 
and T-cells play an important role in AVF maturation, with maturation being promoted 




Furthermore, presence of CD4+ T-cells in mature AVF coincides with the presence of 
macrophages, and the absence of mature T-cells results in reduced macrophage 
infiltration.16,17 Systemic inflammation has been shown to negatively correlate with AVF 
maturation, and higher levels of C-relative protein increase the risk of AVF failure. 
Further, prednisolone, a drug with anti-inflammatory properties, enhances venous 
outward remodeling.18 Use of paclitaxel, a chemotherapeutic and immunosuppressive 
agent, during drug-coated balloon angioplasty leads to inhibition of neointimal 
hyperplasia (NIH) and has shown encouraging 6-month patency rates.19-21 However, 
increased infection rates have become a major concern for paclitaxel use in AVF.22  
Successful AVF maturation relies on venous wall thickening and outward 
remodeling in order to support flow rates required for successful hemodialysis. AVF 
failure occurs via 2 distinct mechanisms; early fistula failure occurs secondary to lack of 
outward remodeling or wall thickening, while late failure occurs as a result of 
development of NIH and impaired outward remodeling in a previously functional 
conduit.23 Unfortunately primary maturation and patency rates of AVF remain low. Up 
to 60% of AVF fail to mature by 5 months after creation, and literature shows primary 
patency rates of 60% at 1 year and 51% at 2 years, with secondary patency rates of 71% 
at 1 year and 64% at 2 years.5,24,25 Factors such as diabetes mellitus, peripheral vascular 
disease, congestive heart failure, and older age are poor prognostic factors for 
successful AVF placement.26 Furthermore, studies have demonstrated prolonged 
maturation time, decreased patency, and increased early thrombosis of AVF in female 




1.3. Akt1 signaling in AVF maturation 
Erythropoietin-producing hepatocellular carcinoma (Eph) receptors with ephrins, 
their ligands, play an essential role in vascular development and determine arterial 
versus venous identities.30,31 Eph receptor activation leads to downstream signaling via 
the PI3K-Akt pathway, resulting in cell migration and proliferation, functions critical for 
venous remodeling.32,33 Specifically, Eph-B4 modulates adaptation and AVF maturation 
with distinct patterns of altered vessel identity.34-36 During successful AVF maturation, 
the venous limb gains expression of ephrin-B2 and has increased Eph-B4 expression, 
relative to control veins, suggesting acquisition of dual arterial-venous identity.12 
Although the route of ephrin-B2 signaling during AVF maturation remains unknown, it 
must be membrane bound and circulating endothelial progenitor cells can be a source.37  
In vivo, Eph-B4 activation attenuates Akt1 phosphorylation leading to reduced 
venous wall thickening, reduced outward remodeling and improved long-term patency 
rates. This was corroborated with constitutively active-Akt1 studies which lead to 
increased venous wall thickening and dominant negative-Akt1 studies which lead to 
reduced outward remodeling.36 Therefore, it is proposed that Eph-B4 can regulate 
venous remodeling via an Akt1-mediated mechanism.36 Moreover, Akt1 expression is 
upregulated during venous remodeling, both during vein graft adaptation,38 as well as 
during AVF maturation, a consistent response to two different hemodynamic 
environments;36 during AVF maturation, Akt1 regulates both venous wall thickening as 
well as dilation.36 Mammalian target of rapamycin (mTOR) is a key regulatory protein 




inflammation and coordinate cell growth and proliferation, all of which occur during 
venous remodeling.39 Rapamycin, an mTOR inhibitor, is currently used for human 








2. Statement of Purpose and Aims 
2.1. Statement of Purpose 
Since rapamycin inhibits Akt1 signaling, and Akt1 mediates venous remodeling, 
we hypothesize that inhibition of the Akt1-mTORC1 axis in macrophages with rapamycin 
alters venous adaptive remodeling in AVF.    
 
2.2. Aims 
Specific Aim I: Determine the effects of rapamycin as a downstream inhibitor of Akt1 
signaling on AVF patency 






3.1. Study Approval 
All animal experiments were performed in strict compliance with federal 
guidelines and with approval from the Yale University IACUC.  
 
3.2. Infrarenal aorto-caval fistula 
Mice used for this study were wild type C57BL6/J. Mice were 9–12 weeks of age 
when the infrarenal aorto-caval fistulae were created as previously described;42,43 only 
male mice were studied since female sex is the only predictor of non-maturation of 
human AVF in some studies.44  Briefly, AVF were created by needle puncture from the 
aorta into the inferior vena cava (IVC) using a 25G needle. Visualization of pulsatile 
arterial blood flow in the IVC was assessed as a technically successful creation of AVF. 
Following surgery, all animals were monitored daily and evaluated weekly by a 
veterinarian for changes in health status. 
 
3.3. Confirmation of fistula patency and measurement of fistula dilation 
Doppler ultrasound (40 MHz; Vevo770 High Resolution Imaging System; Visual 
Sonics Inc., Toronto, Ontario, Canada) was used to confirm the patency of the AVF and 
to measure the diameter of the vessels as previously described.42,43 Doppler ultrasound 
was performed prior to operation (day 0 values) and serially post-operatively. Increased 
end-diastolic flow through the aorta and a high velocity pulsatile flow within the IVC 




confirmed at time of AVF harvest by direct visualization of pulsatile arterial blood flow 
into the IVC, and in all cases correlated with the ultrasound findings. 
 
3.4. Histology 
After euthanasia, the circulatory system was flushed under pressure with PBS 
followed by 10% formalin and the AVF was harvested en bloc. The tissue was then 
embedded in paraffin and cut in 5 μm cross sections. Hematoxylin and eosin staining 
was performed for all samples. Elastin Van Gieson (EVG) staining was used to measure 
intima-media thickness in 5 μm cross sections of the IVC using sections obtained 100-
200 µm cranial to the fistula. Four equidistant points around the IVC and opposite the 
aortic wall were averaged in each cross section to obtain the mean AVF outer wall 
thickness. Additional unstained cross sections in this same region were used for 
immunofluorescence microscopy. 
 
3.5. Immunohistochemistry and Immunofluorescence 
Tissue sections were de-paraffined using xylene and a graded series of alcohols. 
Sections were heated in citric acid buffer (pH 6.0) at 100 °C for 10 min for antigen 
retrieval. The sections were blocked with 5% bovine serum albumin PBS containing 
0.05% Triton X-100 (T-PBS) for 1h at room temperature prior to incubation overnight at 
4 °C with the primary antibodies diluted in T-PBS. All the primary antibodies have been 
listed in the Table 1. Sections were then treated with secondary antibodies at room 




anti-goat Alexa-Fluor-488 (Life Technologies), or donkey anti-rabbit Alexa-Fluor-568 (Life 
Technologies). Sections were stained with Slow Fade® Gold Antifade Mount with DAPI 
(Life Technologies) and coverslip was applied. Digital fluorescence images were 
captured and intensity of immunoreactive signal was measured using Image J software 
(NIH, Bethesda, Maryland). Intensity of the merge signal was determined by applying a 
color threshold selective for the appropriate signal. 
Table 1. List of Antibodies  
Target antigen Vendor or Source Catalog # 
Cleaved caspase-3 Cell Signaling 9664 
proliferating cell nuclear antigen Dako M0879 
Collagen I Novus Biologicals NB600-408 
Collagen III Novus Biologicals NB600-594 
fibronectin Abcam ab2413 
CD68 Bio-Rad MCA1957 
iNOS Cell Signaling 2977S 
interleukin-10 Abcam ab9969 
TNFa Abcam ab9635 
CD206 Bio-Rad MCA2235T 
VECAM1 Abcam ab134047 
ICAM1 R&D Systems AF796-SP 




Akt1 Cell Signaling 2967 
Phospho-mTOR (Ser2481) Cell Signaling 2974 
Phospho-mTOR (Ser2448) Cell Signaling 2971 
phospho-4EBP1 Cell Signaling 2855 
4EBP1 Cell Signaling 9452 
phospho-70SK1 Abcam 17464 
70S6K1 Cell Signaling 9202 
phospho-PKCα Abcam 23513 
PKCα Cell Signaling 2056 
Phospho-SGK1 Thermo Fischer 44-1260G 
SGK1 Abcam 59337 
Alpha-actin Dako M0851 
GAPDH Cell Signaling 2118 
 
3.6. Western Blot 
The venous limb of the AVF was harvested and treated with RIPA lysis buffer 
containing protease inhibitors. Equal amounts of protein were loaded and run in SDS-
PAGE followed by Western blot analysis. Protein expression was probed with the 
antibodies listed in Table 1. 
Membranes were developed using Western Lightning Plus ECL reagent 
(PerkinElmer). Membranes were stripped with Restore Western Blot Stripping Buffer 




Image J and was normalized to GAPDH or the ratio of phosphorylated to total protein 
was calculated.   
 
3.7. Rapamycin and clodronate treatment 
Intraperitoneal (IP) injections of rapamycin (100 µg; #553212, Sigma Aldrich) 
were delivered every 24h beginning on the day of operation and continued throughout 
the study period. In mice treated with adenovirus containing constitutively active Akt1, 
250 µg of rapamycin was used. The control group received an equal volume injection of 
vehicle (DMSO) as control. In the adventitial delivery group, pluronic gel was used to 
deliver 100 µg of rapamycin to the adventitia of the venous AVF wall of at the time of 
surgery. 
Intraperitoneal injections of clodronate-containing liposomes (0.5 mg/Kg; CLD-
8909, Encapsula Nano Sciences) were delivered every 72hr beginning on postoperative 
day 1 and continued throughout the study period. The control group received an equal 
volume injection of vehicle (PBS). Intraperitoneal injections of 20 µg Ephrin-B2/Fc (R&D) 
were delivered 24h prior to AVF creation and every 48h thereafter. Control mice 
received an equal volume injection of vehicle (PBS) as control. 
 
3.8. Adenovirus treatment 
Infrarenal aorto-caval AVF were created as described above. After unclamping 
and confirming fistula flow, 1·106 copies of commercially available vectors (Vector 




Akt1), or a control virus (WT-HA-Akt1) were applied to the AVF adventitial surface in a 
25% w/v pluronic gel. The HA reporter tag in these vectors were used for 
immunofluorescent confirmation of virus delivery. After visual confirmation that the 
pluronic gel mixture had solidified, the abdomen was closed as described above. 
 
3.9. Statistics 
Data are represented as mean value ±SEM. All data were analyzed using Prism 8 
software (GraphPad Software, Inc., La Jolla, CA). The Shapiro-Wilk test was performed to 
analyze normality and the F test was performed to evaluate homogeneity of variances. 
For two-group comparisons with normally distributed data, the unpaired Student’s t test 
was used for data with equal variances among groups and the unpaired Student’s t test 
with Welch correction was used for data with unequal variances. For multiple group 
comparisons with normally distributed data, the one-way ANOVA followed by the 
Sidak’s post-hoc test was used. Patency outcomes were analyzed with the use of 
Kaplan–Meier curves to display the distribution of occlusion events detected over time. 





4.1. Reduced AVF wall thickness, extracellular matrix deposition, SMC and 
macrophages with rapamycin 
To determine the effects of mTOR signaling during venous remodeling such as 
occurs during AVF maturation, we used a mouse model of AVF that recapitulates human 
AVF maturation.43 Aortocaval fistulae were created as previously described and 
afterwards mice received daily intraperitoneal (IP) injections of rapamycin (100 µg) or 
vehicle alone; in mice treated with rapamycin, rapamycin was detectable in serum 
without any systemic signs of immunosuppression or toxicity (Supplemental Figure 1A). 
The IVC of sham-operated and fistula of control-treated and rapamycin-treated mice 
were harvested and analyzed on postoperative days 3, 7 and 21 (Supplemental Figure 
1B). Compared to sham-operated mice, control AVF showed wall thickening that was 
reduced in AVF treated with rapamycin (Fig. 1A and B; Supplemental Figure 1C and D); 
however, there was no significant difference in the dilation of the IVC (Fig. 1C) or the 
aorta (Supplemental Figure 1E), as well as immunoreactivity of p-eNOS-ICAM dual-
positive cells (Fig. 1D; Supplemental Figure 1F), between rapamycin-treated and control 
groups. Since rapamycin treatment reduced AVF wall thickening, we determined the 
effect of rapamycin on components of the AVF wall including several extracellular 
matrix (ECM) proteins as well as endothelial cells (EC),45,46 smooth muscle cells 
(SMC),36,47,48 and macrophages.47,49,50 There was reduced immunoreactivity  
of collagen I, collagen III, and fibronectin in the AVF wall of rapamycin-treated mice, 




Figure 1. Reduced AVF wall thickness, extracellular matrix deposition, SMC and macrophages with 
rapamycin. (A) Representative photomicrographs showing AVF wall thickness in mice treated with 
rapamycin vs. control (day 21). Scale bar, 25 µm. L, lumen. (B) Bar graph showing AVF wall thickness in 
mice treated with rapamycin vs. control; p<0.0001 (ANOVA); *, p<0.0001 (Sidak’s post hoc); n=5-9. (C) 
Line graph showing relative AVF diameter in mice treated with rapamycin vs. control; normalized to day 0; 
p=0.534 (ANOVA); n=6. (D) Bar graphs showing quantification of dual IF after control or rapamycin 
treatment at days 3, 7, 21, normalized to sham. p-eNOS-ICAM1: p<0.1383 (ANOVA); n=4-6. (E) 
Photomicrographs showing representative of extracellular matrix immunoreactive signals in control or 
rapamycin treated groups (day 7). Collagen I or III (red) and fibronectin (green). (F) Bar graphs showing 
quantification of IF, normalized to sham. Collagen I: p<0.0001 (ANOVA); *, p=0.0006, day 7; *, p<0.0001, 
day 21 (post hoc); n=4. Collagen III: p<0.0001 (ANOVA); *, p=0.0122, day 7; *, p<0.0001, day 21 (post 
hoc); n=4. Fibronectin: p<0.0001 (ANOVA); *, p<0.0001 (post hoc); n=5. (G) Bar graphs showing number of 
ICAM-1+, α-actin+ or CD68+ cells in AVF after control or rapamycin treatment. ICAM-1: p=0.7455 (ANOVA). 
n=5. α-actin: p<0.0001 (ANOVA). *, p<0.0002, day 3; *, p<0.0001, day 7; *, p<0.0001, day 21 (post hoc); 
n=5. CD68: p<0.0001 (ANOVA). *, p<0.0001, days 3 and 7; *, p=0.0463, day 21 (post hoc); n=5. (H) 
Photomicrographs showing representative IF of PCNA (red) merged with ICAM, α-actin or CD68 (green), 
and DAPI (blue) in AVF of control vs rapamycin treated mice (day 7); L, lumen; scale bar, 25 μm. White 
arrowheads indicate merged signal. (I) Bar graphs showing percentage of dual positive cells. PCNA-ICAM: 
p=0.4137 (ANOVA). n=4-5. PCNA-α-actin: p<0.0001 (ANOVA). *, p<0.0001, day 3; *, p=0.0011, day 7 (post 
hoc); n=4-5. PCNA-CD68: p<0.0001 (ANOVA). *, p=0.0002, day 3; *, p=0.0023, day 7 (post hoc); n=4-5. (J) 
Photomicrographs showing representative IF of cleaved caspase-3 (red) merged with ICAM, α-actin or 
CD68 (green), and DAPI (blue) in AVF of control or rapamycin treated mice (day 7); L, lumen; scale bar, 
25 μm. White arrowheads indicate merged signal. (K) Bar graphs showing percentage of dual positive 
cells. Cleaved caspase-3-ICAM: p=0.08777 (ANOVA); n=4-5. Middle graph, cleaved caspase-3-α-actin: 




numbers of α-actin-positive cells and CD68-positive cells, without any change in 
numbers of intercellular adhesion molecule-1 (ICAM-1)-positive cells, in the AVF of 
rapamycin-treated mice compared to control mice, consistent with reduced numbers of 
SMC and macrophages but not EC with rapamycin treatment (Fig. 1G; Supplemental 
Figure 1H). The reduced number of α-actin-positive cells and CD68-positive cells with 
rapamycin treatment was associated with reduced PCNA immunoreactivity (Fig. 1H and 
I; Supplemental Figure 1I); however, there was no increase in cleaved caspase-3 
immunoreactivity with rapamycin treatment (Fig. 1J and K; Supplemental Figure 1J). 
These data suggest that the reduced AVF wall thickening with rapamycin treatment is 
associated with less SMC and macrophage proliferation. 
 
4.2. Reduced M1- and M2-type macrophages with rapamycin 
Since rapamycin treatment was associated with reduced macrophage 
proliferation (Fig. 1), we determined whether rapamycin had differential effects on 
macrophage subpopulations. The wall of the rapamycin-treated AVF showed decreased 
iNOS and TNF-a immunoreactive protein, markers of M1-type macrophages, as well as 
decreased IL-10 and CD206 protein, markers of M2-type macrophages, at both days 3 
and 7 (Fig. 2A and B). Rapamycin-treated AVF also showed reduced immunoreactivity of 
CD68-iNOS dual-positive cells as well as CD68-TNF-a dual-positive cells in the adventitia 
(Fig. 2C and D; Supplemental Figure 2A); there was also reduced immunoreactivity of 
CD68-IL-10 dual-positive cells as well as CD68-CD206 dual-positive cells in the adventitia, 





Figure 2. Reduced M1- and M2-type macrophages with rapamycin. (A) Representative Western blot 
showing iNOS, TNF-α, IL-10 and CD206 protein expression levels in AVF treated with rapamycin or 
control (day 3 and 7). (B) Graphs showing densitometry measurements of iNOS, TNF-α, IL-10 and 
CD206 expression in the AVF after control or rapamycin treatment, normalized to GAPDH. iNOS: 
p=0.0011 (ANOVA). *, p=0.0241, day 3; *, p=0.0054, day 7 (post hoc); n= 2-3. TNF-α: *p=0.0020 
(ANOVA). *, p=0.0223, day 3; *, p=0.0250, day 7 (post hoc); n= 2-3. IL-10: *p<0.0001 (ANOVA). *, 
p=0.0011, day 3; *, p=0.0006, day 7 (post hoc); n= 2-3. CD206: p=0.0013 (ANOVA). *, p=0.0126, day 
3; *, p=0.0200, day 7 (post hoc); n= 2-3. (C) Photomicrographs showing representative dual IF for 
CD68 (red) and iNOS (green, top row) or CD68 (red) and TNF-a (green, bottom row) in AVF after 
control or rapamycin treatment (day 7). Scale bar, 25 μm. L, lumen. (D) Bar graphs showing 
quantification of dual IF after control or rapamycin treatment. Left graph, iNOS-CD68: p<0.0001 
(ANOVA). *, p=0.0006, day 3; *, p=0.0004, day 7; *, p=0.0073, day 21 (post hoc); n=5. Right graph, 
TNF-a-CD68: p<0.0001 (ANOVA). *, p<0.0001, day 3; *, p<0.0001, day 7 (post hoc); n=5. (E) 
Photomicrographs showing representative dual IF for CD68 (red) and IL-10 (green, top row) and CD68 
(red) and CD206 (green, bottom row) in control or rapamycin treated AVF (day 7). (F) Bar graphs 
showing quantification of dual IF after control or rapamycin treatment (day 7). Left graph, IL-10-
CD68: p<0.0001 (ANOVA). *, p<0.0001, day 3; *, p<0.0001, day 7 (post hoc); n=5. CD206-CD68: 
p<0.0001 (ANOVA). *, p<0.0001, day 3; *, p<0.0001, day 7 (post hoc); n=5. (G) Photomicrograph of 
representative of CD45+ cells in control or rapamycin treated mice AVF (day 7). (H) Bar graph 
showing number of CD45 immunoreactive cells in AVF after control vs rapamycin treatment; 
p<0.0001 (ANOVA); *, p<0.0001, day 3; *, p=0.0020, day 7; *, p=0.2110, day 21 (post hoc); n=5. (I) 
Representative photomicrographs showing VCAM-1 (top row) and ICAM-1 (bottom row) IF in AVF 
after control or rapamycin treatment (day 7). (J) Bar graphs showing relative quantification of VCAM-
1 and ICAM-1 intensity in AVF, normalized to sham vessels. VCAM-1: p=0.3162 (ANOVA); n=6. ICAM-




also associated with fewer number of leukocyte common antigen (CD45) 
immunoreactive cells (Fig. 2G and H; Supplemental Figure 2C), but there was no 
difference in immunoreactivity of vascular cell adhesion molecule-1 (VCAM-1) or ICAM-1 
(Fig. 2I and J; Supplemental Fig. 2D). These data suggest that rapamycin is associated 
with reduced immunoreactivity of both M1-type and M2-type macrophages as well as 
fewer leukocytes during AVF remodeling. 
 
4.3. Reduced Akt1 and mTORC1 but not mTORC2 phosphorylation with rapamycin 
Since mTOR binds to either the Raptor regulatory subunit to form mTORC1, a 
downstream target of Akt1,51 or to the Rictor regulatory subunit to form mTORC2,52 an 
upstream regulator of Akt1,39 we next determined whether rapamycin altered the 
phosphorylation of either of these complexes during AVF remodeling.  Rapamycin was 
associated with reduced numbers of p-Akt1 immunoreactive cells (days 7 and 21) and p-
mTORC1 immunoreactive cells (days 3 and 7), but there was no difference in the 
numbers of p-mTORC2 immunoreactive cells (Fig. 3A and B; Supplemental Figure 3A). 
Similarly, mice treated with rapamycin had decreased expression of phosphorylated 
Akt1 and phosphorylated mTORC1, with no significant change in expression of 
phosphorylated mTORC2, in the AVF wall (days 3-21; Fig. 3C and D). Reduced Akt1 and 
mTORC1 phosphorylation with rapamycin was similarly reduced in both p-Akt1-α-actin 
dual-positive cells as well as p-mTORC1-α-actin dual-positive cells (Fig. 3E and F; 
Supplemental Figure 3D); immunoreactivity was also reduced with rapamycin 





Figure 3. Reduced Akt1 and mTORC1 but not mTORC2 phosphorylation with rapamycin. (A) 
Photomicrographs showing representative IF of p-Akt1+ (top, red), p-mTORC1+ (middle, red) and 
p-mTORC2+ (bottom, red) cells in control or rapamycin treated mice AVF (day 7). Scale bar, 
25μm. L, lumen. (B) Bar graphs showing number of p-Akt1+, p-mTORC1+ and p-mTORC2 + cells in 
AVF after rapamycin or control treatment. p-Akt-1: *, p<0.0001 (ANOVA); *, p<0.0001, day 7; *, 
p =0.0105, day 21 (post hoc); n=4-5. p-mTORC1: p<0.0001 (ANOVA); *, p<0.0001, day 3; *, 
p<0.0001, day 7 (post hoc); n=4-5. p-mTORC2: p=0.2870 (ANOVA); n=4-5. (C) Representative 
Western blot showing Akt1, mTORC1, mTORC2 phosphorylation level after control vs rapamycin 
treatment. (D) Graphs showing densitometry measurement of Akt1, mTORC1 and mTORC2 
phosphorylation. p-Akt1: tAkt1, p=0.0002 (ANOVA); *, p=0.0110, day 7; *, p=0.0359, day 21 
(post hoc); n=3. p-mTORC1: tmTORC1, p=0.0004 (ANOVA); *, p=0.0157, day 3; *, p=0.0192, day 
7; *, p=0.0366, day 21 (post hoc); n=3. p-mTORC2: tmTORC2: P=0.9893 (ANOVA); n = 3. (E) 
Photomicrographs showing representative IF of dually-positive α-actin (green) and p-Akt1 (red, 
first row) or p-mTORC1 (red, second row) in AVF after control or rapamycin treatment (day 7). (F) 
Bar graphs showing quantification of dual IF after control vs rapamycin treatment. P-Akt1-α-
actin: p<0.0001 (ANOVA); *, p=0.0002, day 7; *, p=0.0017, day 21 (post hoc); n=4-5. p-mTORC1-
α-actin: p<0.0001 (ANOVA); *, p=0.0136, day 7; *, p<0.0001, day 21 (post hoc); n=4. (G) 
Photomicrographs showing representative dual IF for CD68 (green) and p-Akt1 (red, top row) or 
p-mTORC1 (red, bottom row) in AVF after control or rapamycin treatment (day 7). (H) Bar graphs 
showing quantification of dual IF after control vs rapamycin treatment. p-Akt1-CD68: p<0.0001 
(ANOVA); *, p=0.0013, day 7; *, p=0.0183, day 21 (post hoc); n=4-5. p-mTORC1-CD68: p<0.0001 




cells (Fig. 3G and H; Supplemental Figure 3E). However, there was no significant 
difference in immunoreactivity of p-Akt1-ICAM dual-positive cells or p-mTORC1-ICAM 
dual-positive cells with rapamycin treatment (Supplemental Figure 3B and C). These 
data suggest that rapamycin is associated with less Akt1-mTORC1 signaling, in both SMC 
and macrophages, during AVF remodeling. 
Since these data show that rapamycin reduces mTORC1, but not mTORC2, 
phosphorylation (Fig. 3), we evaluated the phosphorylation of P70S6K and 4EBP1, 
downstream targets of mTORC1.53 There were significantly fewer number of cells that 
were immunoreactive for p-P70S6K1 or p-4EBP1 in the AVF of mice treated with 
rapamycin compared to control (Fig. 4A; Supplemental Figure 4A); however, there was 
no effect on the number of cells that were immunoreactive for p-PKCα or p-SGK1, 
downstream targets of mTORC2 (Fig. 4B; Supplemental Figure 4B). Similarly, AVF 
treated with rapamycin had significantly decreased expression of phosphorylated 
P70S6K and 4EBP1 (Fig. 4C and D), but no significant change in expression of 
phosphorylated PKCα or SGK1 (Fig. 4E; Supplemental Figure 4C). These results suggest 
that rapamycin regulates the mTORC1, but not mTORC2 pathway, during venous 
remodeling. 
The AVF of mice treated with rapamycin similarly showed decreased 
immunoreactivity of p-P70S6K-α-actin dual-positive cells and p-4EBP1-α-actin dual-
positive cells (Fig. 4F and G; Supplemental Figure 4D); rapamycin-treated AVF also 
showed decreased immunoreactivity of p-P70S6K-CD68 dual-positive cells and p-4EBP1-





Figure 4. Reduced p70S6K1 and 4EBP1, but not PKCα or SGK1, phosphorylation with 
rapamycin. (A) Bar graphs showing number of p-p70S6K1+ and p-4EBP1+ cells in AVF after 
rapamycin and control treatment. Top graph, p-p70S6K1: p<0.0001 (ANOVA). *, p<0.0001, day 3; 
*, P <0.0001, day 7; *P <0.0001 at day 21 (post hoc); n=4-6. Bottom graph, p-4EBP1: p<0.0001 
(ANOVA). *, p<0.0001, day 3; *, p<0.0001, day 7; *, p=0.0010, day 21 (post hoc); n=5-7. (B) Bar 
graphs showing number of cells in AVF after control vs rapamycin treatment. Top graph, p-PKCα: 
p=0.5130 (ANOVA); n=5. Bottom graph, p-SGK1: p=0.2569 (ANOVA); n=4-5. (C) Representative 
Western blot showing p70S6K1 and 4EBP1 phosphorylation after control vs rapamycin 
treatment. (D) Graphs showing densitometry measurement of p70S6K1 and p-4EBP1 
phosphorylation. p-p70S6K1: t p70S6K1, p<0.0001 (ANOVA). *, p=0.0024, day 7; *, p=0.0024, day 
21 (post hoc). n=3. p-4EBP1: t4EBP1, P <0.0001 (ANOVA). *, p=0.0007, day 3; *, p<0.0001, day 7; 
*, p=0.0053, day 21 (post hoc). n=3. (E) Graphs showing densitometry measurement of PKCα and 
SGK1 phosphorylation. p-PKCα: tPKCα, p=0.9280 (ANOVA); n=3. p-SGK1: tSGK1, p=0.6075 
(ANOVA). n=3. (F) Photomicrographs of representative IF for α-actin (green) and p-P70S6K1 (red, 
top row) or p-4EBP1 (red, bottom row) in AVF after control or rapamycin treatment; day 7. (G) 
Bar graphs showing quantification of dual IF after control or rapamycin treatment, normalized to 
sham vessels. p-P70S6K1-α-actin: p<0.0001 (ANOVA); *, p=0.0002, day 3; *, p<0.0001, day 7; *, 
p=0.0030, day 21 (post hoc); n=4-5. p-4EBP1-α-actin: p<0.0001 (ANOVA); *, p=0.0378, day 3; *, 
p<0.0001, day 7; *, p=0.0109, day 21 (post hoc); n=4-5. (H) Representative photomicrographs of 
IF images for CD68 (green) and p-P70S6K1 (red, top row) or p-4EBP1 (red, bottom row) in AVF 
after control or rapamycin treatment (day 7). (I) Bar graphs showing quantification of dual IF 
after control or rapamycin treatment, normalized to sham vessels. p-P70S6K1-CD68: p<0.0001 
(ANOVA); *, p<0.0001, day 3; *, p<0.0001, day 7 (post hoc); n=4-5. p-4EBP1-CD68: p<0.0001 





difference in immunoreactivity of p-PKCα-α-actin dual-positive cells or p-SGK1-α-actin 
dual positive cells with rapamycin or control treatments (Supplemental Figure 4F, 4G); 
there was also no difference in immunoreactivity of p-PKCα-CD68 dual-positive cells or 
p-SGK1-CD68 dual positive cells (Supplemental Figure 4H, 4I). These results show that 
rapamycin is associated with less Akt1-mTORC1, but not mTORC2, signaling in SMC and 
macrophages, during AVF remodeling. 
Since rapamycin inhibits both wall thickness as well as Akt1 and mTORC1 
phosphorylation in SMC and macrophages during AVF maturation, we next determined 
if the Akt1-mTORC1 axis regulates AVF remodeling. We previously showed that Eph-B4 
activation with Ephrin-B2/Fc inhibits Akt1 function in vivo during venous remodeling;36 
accordingly, we used Ephrin-B2/Fc to inhibit the Akt1-mTORC1 axis. As expected, 
Ephrin-B2/Fc decreased immunoreactivity of p-Akt1-α-actin dual-positive cells; Ephrin-
B2/Fc also diminished p-mTORC1-α-actin dual-positive cells, but not mTORC2-α-actin 
dual-positive cells, in the absence of rapamycin (Fig. 5A and B). These data suggest that 
diminished Akt1 activity reduces mTORC1 phosphorylation during venous remodeling. 
We next examined whether increased Akt1 activity is associated with increased 
mTORC1 phosphorylation in vivo during AVF maturation. At the time of AVF creation, 
either control vehicle, wild type (WT)-Akt1 adenovirus (Ad), or constitutively active (CA)-
Akt1 adenovirus was placed in pluronic gel on the adventitia of the AVF; viral vectors 
were found within the EC, SMC, and macrophages in the AVF wall, and both viral vectors 
had similarly high rates of efficiency (Supplemental Fig. 5A and B). AVF treated with Ad-




or Ad-WT-Akt1 (Fig. 5C and D). AVF treated with control or Ad-WT-Akt1 showed similar 
outward remodeling (Supplemental Figure 5C). Daily IP injections of rapamycin 
attenuated the increase in wall thickening in AVF treated with Ad-CA-Akt1 (Fig. 5C and 
D). Similarly, there was increased phosphorylation of Akt1 and mTORC1 in AVF treated 
with Ad-CA-Akt1, compared to those treated with Ad-WT-Akt1 or control, and 
rapamycin attenuated phosphorylation of mTORC1, but not Akt1, in AVF treated with 
CA-Akt1 (Fig. 5E and F). In mice treated with rapamycin, there was no sign of clinical 
toxicity or significant differences in weight change at day 21 compared to the control 
group (Supplemental Figure 5D). 
Since rapamycin is associated with reduced mTORC1 phosphorylation in the wall 
of the remodeling AVF (Fig. 3C, 3D; Fig. 5E, 5F), we next determined whether the 
inhibitory effects of rapamycin were present in either SMC or macrophages. As 
expected, there was increased immunoreactivity of p-Akt1-α-actin dual-positive cells 
and p-mTORC1-α-actin dual-positive cells in AVF treated with Ad-CA-Akt1 compared to 
control or Ad-WT-Akt1. Rapamycin reduced the immunoreactivity of p-mTORC1-α-actin 
dual-positive cells, but not p-Akt1-α-actin dual-positive cells, in the AVF treated with Ad-
CA-Akt1 (Fig. 5G; Supplemental Figure 5E). Similarly, rapamycin reduced the 
immunoreactivity of p-mTORC1-CD68 dual-positive cells, but not p-Akt1-CD68 dual-
positive cells, in the AVF treated with Ad-CA-Akt1 (Fig. 5H; Supplemental Figure 5F). 
These results suggest that rapamycin inhibits mTORC1 signaling in both SMC and 






Figure 5. Rapamycin inhibits mTORC1 phosphorylation during venous remodeling. (A) Photomicrographs of 
representative dual p-Akt1-α-actin (top), p-mTORC1-α-actin (middle) and p-mTORC2-α-actin (bottom) IF in 
control or Ephrin-B2/Fc treated mice AVF (day 21). Scale bar, 25μm. L, lumen. (B) Bar graphs showing 
quantification of dual p-Akt1-α-actin, p-mTORC1-α-actin, and p-mTORC2-α-actin IF after control or Ephrin-B2/Fc 
treatment. p-Akt1-α-actin: *, p=0.0027 (t-test). p-mTORC1-α-actin: *, p<0.0001 (t-test). p-mTORC2-α-
actin, p=0.8342 (t-test). n=4-5. (C) Photomicrographs showing representative AVF wall thickness in mice treated 
with control, Ad-WT-Akt1, Ad-CA-Akt1, and Ad-CA-Akt1 with daily 250 μg IP rapamycin injection (day 21). 
Arrowheads denote vessel wall thickness. Scale bar, 25 µm. (D) Bar graph showing AVF wall thickness in mice 
treated with pluronic gel containing control, WT-Akt1, constitutively active (CA-) Akt1, and CA-Akt1 with 250 μg 
rapamycin (day 21), p<0.0001 (ANOVA); control vs WT-Akt1: p >0.9999; control vs CA-Akt1: *, p<0.0001; Control 
vs. CA-Akt1+Rapa: p=0.0789; WT-Akt1 vs. CA-Akt1: *, p<0.0001; WT-Akt1 vs. CA-Akt1+Rapa: p=0.0944; CA-Akt1 
vs. CA-Akt1+Rapa: *, p<0.0001 (post-hoc). n=4-5. (E) Representative Western blot showing expression level of 
Akt1, p-Akt1, mTORC1 and p-mTORC1 in AVF treated with control, Ad-WT-Akt1, Ad-CA-Akt1, and Ad-CA-Akt1 
with rapamycin. (F) Graphs with densitometry measurement of Akt1 and mTORC1 phosphorylation. p-Akt1: t 
Akt1: p=0.0015 (ANOVA); Control vs. WT-Akt1: p=0.5435; Control vs. CA-Akt1: *, p=0.0066; Control vs. CA-
Akt1+Rapa: *, p=0.0019; WT-Akt1 vs. CA-Akt1: *, p=0.0147; WT-Akt1 vs. CA-Akt1+Rapa: *, p=0.0035; CA-Akt1 
vs. CA-Akt1+Rapa: p=0.1536 (post hoc); n=3. p-mTORC1: tmTORC1, P =0.0025 (ANOVA). Control vs. WT-Akt1: 
p=0.8142; Control vs. CA-Akt1: *, p=0.0076; Control vs. CA-Akt1+Rapa: p=0.1209; WT-Akt1 vs. CA-Akt1: *, 
p=0.0125; WT-Akt1 vs. CA-Akt1+Rapa: p=0.0566; CA-Akt1 vs. CA-Akt1+Rapa: *, p=0.0019 (post hoc). n=3. (G) 
Bar graphs showing quantification of dual IF after delivery of control, Ad-WT-Akt1, Ad-CA-Akt1, and Ad-CA-
Akt1+rapamycin. p-Akt1-α-actin: p<0.0001 (ANOVA); control vs. CA-Akt1: *, p=0.0001; control vs. CA-
Akt1+Rapa:  p=0.0015; WT-Akt1 vs. CA-Akt1: *, p=0.0003; WT-Akt1 vs. CA-Akt1+Rapa: p=0.0033 (post hoc). n=4-
5. p-mTORC1-α-actin: p<0.0001 (ANOVA); control vs. CA-Akt1: *, p=0.0007; WT-Akt1 vs. CA-Akt1: p=0.0013; CA-
Akt1 vs. CA-Akt1+Rapa: **p<0.0001 (post hoc); n=4-5. (H) Bar graphs showing quantification of dual IF after 
local delivery of control, WT-Akt1, constitutively active CA-Akt1, and CA-Akt1 with rapamycin. p-Akt1-CD68: 
p=0.4265 (ANOVA); control vs. CA-Akt1: *, p=0.0041; control vs. CA-Akt1+Rapa: p=0.0003; WT-Akt1 vs. CA-Akt1: 
p=0.0214; WT-Akt1 vs. CA-Akt1+Rapa: *, p=0.0013 (post hoc); n=4-5. p-mTORC1-CD68: p=0.4662 (ANOVA). 
control vs. CA-Akt1: *, p=0.0422; control vs. CA-Akt1+Rapa: p=0.0025; WT-Akt1 vs. CA-Akt1: p=0.0036; WT-Akt1 




4.4. Macrophage depletion is associated with reduced AVF wall thickness and patency  
We have previously shown that M2-type macrophages play a role during venous 
remodeling such as occurs during vein graft adaptation54 and AVF maturation;15 delivery 
of MCP-1 to the AVF adventitia increased M2-type macrophages and increased AVF wall 
thickness.15 Since our data suggest that rapamycin has an effect on macrophage 
proliferation (Fig. 1), M1 and M2 marker expression (Fig. 2), and Akt1-mTORC1 signaling 
(Fig. 3-5), we next examined whether depletion of macrophages would improve AVF 
patency. After IP injections of clodronate-containing liposomes, there were significantly 
reduced numbers of CD68 immunoreactive cells in the AVF wall (Supplemental Figure 
6A). Macrophage depletion was associated with reduced wall thickening that was 
characterized by fewer α-actin immunoreactive cells (day 21; Fig. 6A and B). There was 
also reduced immunoreactivity of p-Akt1-α-actin dual-positive cells and p-mTORC1-α-
actin dual-positive cells, but no change in p-mTORC2-α-actin dual-positive cells, in 
macrophage-depleted AVF compared to control (Fig. 6C and D). Clodronate increased 
the number of apoptotic macrophages but had no effect on EC or SMC apoptosis (Fig. 6E 
and F); there was no compensatory increase in proliferation in any cell type (Fig. 6G and 
H). At day 7, clodronate-treated AVF showed reduced immunoreactivity of CD68-iNOS, 
CD68-TNF-a, CD68-IL-10 and CD68-CD206 dual-positive cells in the adventitia compared 
with control AVF (Supplemental Figure 6B). However, at day 21, there was little 
immunoreactivity of CD68-iNOS dual-positive cells or CD68-TNF-a dual-positive cells in 
either control AVF or clodronate-treated AVF; interestingly, control AVF had some 





Figure 6. Macrophage depletion is associated with reduced AVF wall thickness and patency. (A) 
Representative photomicrographs showing AVF wall thickness and number of α-actin+ cells in mice treated 
with clodronate vs. control (day 21). Scale bar, 25 µm. L, lumen (B) Bar graphs showing AVF wall thickness 
(left) and number of α-actin+ cells (right) in AVF after control or clodronate treatment; *p=0.0005 (t test); 
n=5. α-actin+ cell number: *p<0.0001 (t test); n=5. (C) Representative photomicrographs showing dual IF 
for a-actin (green) and p-Akt1 (red, first row), p-mTORC1 (red, second row) or p-mTORC2 (red, third row) in 
AVF after control or clodronate treatment (day 21). (D) Bar graph showing quantification of dual IF in AVF 
after control or clodronate treatment. p-Akt1-α-actin: *, p<0.0001 (t test); n=5. p-mTORC1-α-actin: *, 
p=0.0011 (t test); n=5. p-mTORC2-α-actin: p=0.5549 (t test); n=5. (E) Photomicrographs showing 
representative IF of cleaved caspase-3 (red) merged with ICAM, α-actin or CD68 (green), and DAPI (blue) in 
AVF of control or clodronate treated mice (day 7); L, lumen; scale bar, 25 μm. White arrowheads indicate 
merged signal. (F) Bar graphs showing percentage of dual positive cells (day 21). Cleaved caspase-3-ICAM: 
p>0.9999 (t test); n=4-5. Cleaved caspase-3-α-actin: p=0.9315 (t test). n=4-5. Cleaved caspase-3-CD68: 
*p=0.0027 (t test). n= 4-5.(G) Photomicrographs showing representative IF of PCNA (red) merged with 
ICAM, α-actin or CD68 (green), and DAPI (blue) in AVF of control or clodronate treated mice (day 7); L, 
lumen; scale bar, 25 μm. White arrowheads indicate merged signal. (H) Bar graph showing percentage of 
dual positive cells (day 21). PCNA-ICAM positive cells: p=0.8139 (t test); PCNA-α-actin: *, P =0.0035 (t test); 
PCNA-CD68: p=0.8547 (t test). n=4-5. (I) Representative photomicrographs showing dual IF for CD68 (red) 
and iNOS (green, top row), TNF-a (green, second row), IL-10 (green, third row) or CD206 (green, bottom 
row) in AVF after control or clodronate treatment; day 21. Scale bar, 25 μm. L, lumen. (J) Bar graphs 
showing quantification of dual IF after control or clodronate treatment (day 21). CD68-iNOS: p=0.7311 (t 
test). CD68-TNF-a: p<0.8422 (t test). CD68-IL-10: p<0.0001 (t test). CD68-CD206: p=0.0006 (t test). n=5. (K) 
Line graph showing AVF patency rate in mice treated with control or clodronate IP injections. *P = 0. 




 that were not observed with clodronate treatment (Fig. 6I and J). Because macrophage 
depletion was associated with reduced AVF wall thickness, we next assessed whether 
the reduced number of macrophages was also associated with altered AVF patency. 
Macrophage depletion significantly reduced the AVF patency by day 28 (Fig. 6K). These 
data are consistent with clodronate depletion of both M1- and M2-type macrophages 
during AVF maturation and suggest a mechanistic role for macrophages during AVF 
adaptive remodeling. 
 
4.5. Rapamycin treatment is associated with reduced AVF wall thickness but increased 
AVF patency  
The mouse AVF model is characterized by increased wall thickness and dilation 
between days 0 and 28, mimicking human AVF maturation; however, between days 28 
and 42 there is increased neointimal hyperplasia and loss of patency in approximately 
1/3 of mice, mimicking human AVF late failure.42 Since rapamycin treatment was 
associated with reduced AVF wall thickness and attenuated SMC and macrophage 
proliferation (Fig. 1), we determined the effects of rapamycin on AVF patency; daily 
rapamycin or control vehicle injection was continued up to postoperative day 42.  In 
mice treated with rapamycin daily, there was no sign of clinical toxicity or significant 
differences in weight change compared to control mice (Supplemental Figure 7A); there 
was also no difference in the technical success rate of AVF creation in rapamycin treated 
mice compared to control mice (Supplemental Figure 7B). Rapamycin-treated mice 




AVF patency if rapamycin was delivered directly to the adventitia in a single dose at the 
time of AVF creation (Supplemental Figure 7B). Mice treated with IP injections of 
rapamycin had AVF that showed less thickening but a similar rate of dilation compared 
to control mice (Fig. 7B-D).  
At day 42, rapamycin-treated AVF showed fewer number of α-actin 
immunoreactive cells, with no change in the number of CD68 immunoreactive cells, 
compared with control AVF (Fig. 7E and F). AVF of rapamycin treated mice showed 
reduced immunoreactivity of α-actin-mTORC-1 dual-positive cells without any change in 
immunoreactivity of α-actin-p-Akt1 dual-positive cells or α-actin-p-mTORC2 dual-
positive cells (Fig. 7G and H). However, AVF of rapamycin treated mice had similar 
immunoreactivity of p-Akt1-CD68 dual-positive cells, p-mTORC1-CD68 dual-positive cells 
and p-mTORC2-CD68 dual-positive cells compared to control (Fig. 7I and J). In toto, 
these data suggest that rapamycin has sustained inhibition of mTORC1 activity in SMC, 
reducing wall thickness and improving AVF patency. 
 
4.6. Rapamycin enhances early AVF remodeling to improve patency  
To determine whether the increased patency rate observed after rapamycin 
treatment is due to enhancement of AVF remodeling during the early maturation phase 
or due to reduced neointimal hyperplasia during later remodeling, rapamycin treatment 
was given either only from day 1-21 (early rapamycin) or only from day 22-42 (late 
rapamycin); control AVF received only vehicle injections from day 1-42. Compared to 





Figure 7. Rapamycin treatment is associated with reduced AVF wall thickness but increased 
AVF patency. (A) Line graph showing AVF patency rate in mice treated with control vs rapamycin 
IP injections. *P = 0.0495 (Log-rank), n=13-14 in each arm. (B) Representative photomicrographs 
showing AVF wall thickness in mice treated with control or rapamycin (day 42). Arrowheads 
denote wall thickness. Scale bar, 25μm. L, lumen. (C) Bar graph showing AVF wall thickness in 
after control or rapamycin treatment (Day 42); *p<0.0001 (t test). n=5. (D) Line graph showing 
relative AVF diameter in mice treated with control or rapamycin, normalized to day 0; p=0.2603 
(ANOVA); n=6-8. (E) Photomicrographs of representative IF of α-actin+ (top row) and CD68+ cells 
(bottom row) in control or rapamycin treated mice AVF (day 42). (F) Bar graphs quantifying 
number of α-actin+ (left) and CD68+ cells (right) in AVF after control or rapamycin treatment; α-
actin: *p<0.0001 (t-test); CD68: p=0.2643 (t test); day 42. n=5. (G) Photomicrographs of 
representative dual IF of a-actin (green) and p-Akt1 (red, first row), p-mTORC1 (red, second row) 
or p-mTORC2 (red, third row) in AVF after control or rapamycin treatment (day 42). (H) Bar 
graphs showing quantification of dual IF in AVF after control or rapamycin treatment (day 42). p-
Akt1-α-actin: p=0.8126 (t test); p-mTORC1-α-actin: *, p=0.0026 (t test). p-mTORC2-α-actin: 
p=0.3206 (t test); n=5. (I) Photomicrographs of representative dual IF for CD68 (green) and p-
Akt1 (red, first row), p-mTORC1 (red, second row) or p-mTORC2 (red, third row) in AVF after 
control or rapamycin treatment (day 42). (J) Bar graphs showing quantification of dual IF in AVF 
after control or rapamycin treatment (Day 42). p-Akt1-CD68: p=0.5195 (t test). p-mTORC1-CD68: 





improved AVF patency by day 42; however, compared to control mice, there was no 
significant improvement in AVF patency with late rapamycin treatment (Fig. 8A). Mice 
treated with early rapamycin, but not late rapamycin, had AVF that showed reduced 
thickening, compared to control mice (Fig. 8B and C). Mice treated with early rapamycin 
and late rapamycin had a similar rate of dilation compared to control mice (Fig. 8D). 
At day 42, AVF treated with early rapamycin, but not AVF treated with late 
rapamycin, showed fewer number of α-actin immunoreactive cells, compared to control 
AVF (Fig. 8E and F). However, AVF treated with control, early rapamycin or late 
rapamycin showed no difference in the number of CD68 immunoreactive cells (Fig. 8E 
and F). AVF treated with control, early rapamycin or late rapamycin also showed similar 
immunoreactivity of α-actin-p-Akt1 dual-positive cells (Fig. 8G and H). AVF treated with 
late rapamycin, but not AVF treated with early rapamycin, had reduced 
immunoreactivity of α-actin-p-mTORC1 dual-positive cells compared to control (Fig. 8G 
and H). AVF treated with control, early rapamycin, or late rapamycin had similar 
immunoreactivity of p-Akt1-CD68 dual-positive cells and p-mTORC1-CD68 dual-positive 
cells (Fig. 8I and J). These data suggest that rapamycin improves AVF patency by 
enhancing AVF remodeling during the early phase of maturation, whereas rapamycin 






Figure 8. Rapamycin enhanced early AVF remodeling to improve patency. (A) Line graph showing AVF 
patency rate in mice treated with control, early vs late rapamycin. Control vs early rapamycin: P=0.0591 
(Log-rank); control vs late rapamycin: P=0.812 (Log-rank); n=5-6 in each group. (B) Representative 
photomicrographs showing AVF thickness in mice treated with control, early rapamycin or late 
rapamycin (day 42). Arrowheads denote wall thickness. (C) Bar graph showing AVF wall thickness in 
after control, early rapamycin or late rapamycin treatment (Day 42); p<0.0001 (ANOVA); control vs 
early rapamycin: p<0.0001 (ANOVA); n=5. (D) Line graph showing relative AVF diameter in mice treated 
with control, early rapamycin or late rapamycin, normalized to day 0; p=0.6767 (ANOVA); n=5-6. (E) 
Photomicrographs of representative IF of α-actin+ (top row) and CD68+ cells (bottom row) in control, 
early or late rapamycin treated AVF (day 42). (F) Bar graphs quantifying number of α-actin+ and CD68+ 
cells in AVF after control, early rapamycin or late rapamycin treatment; α-actin: p<0.0001 (ANOVA); *, 
p<0.0001, control vs early rapamycin; CD68: p=0.0813 (ANOVA); day 42. n=4-5. (G) Photomicrographs 
of representative dual IF of a-actin (green) and p-Akt1 (red, first row) or p-mTORC1 (red, second row) 
in AVF after control, early or late rapamycin treatment (day 42). (H) Bar graphs showing quantification 
of dual IF in AVF after control, early rapamycin or late rapamycin treatment (day 42); p-Akt1-α-actin: 
p=0.6067 (ANOVA); p-mTORC1-α-actin: *, p=0.0003 (ANOVA); control vs late rapamycin: p=0.009; n=5. 
(I) Photomicrographs of representative dual IF for CD68 (green) and p-Akt1 (red) or p-mTORC1 (red) in 
AVF after control, early rapamycin or late rapamycin treatment (day 42). (J) Bar graphs showing 
quantification of dual IF in AVF after control, early rapamycin or late rapamycin treatment (Day 42). p-





This study shows that rapamycin reduces wall thickening and early inflammation 
in AVF as well as proliferation in SMC and macrophages (Fig. 1), suppressing both M1 
and M2 macrophage subtypes (Fig. 2). Rapamycin also inhibits Akt1-mTORC1 
phosphorylation and downstream signaling in both SMC and macrophages during early 
AVF remodeling (Fig. 3 and 4). Macrophage depletion with clodronate reduces wall 
thickening but is accompanied by reduced AVF patency with reduced numbers of M1- 
and M2-type macrophages (Fig. 6). However, rapamycin leads to persistently reduced 
AVF wall thickening and improved patency by enhancing AVF remodeling during the 
early phase of remodeling (Fig. 7 and 8). These results suggest that rapamycin improves 
AVF remodeling and long-term patency by reducing inflammation and cell proliferation 
during early maturation; in addition, macrophages are necessary for adaptive venous 
remodeling.  
Our primary finding is that rapamycin improves AVF patency while reducing wall 
thickening during the early phase of maturation, with no effect on AVF dilation. Given 
the need for therapies that improve vascular access patency, rapamycin and other 
antiproliferative agents are currently being investigated in clinical studies. A recent 
clinical trial studied a rapamycin-eluting collagen membrane in 12 patients and showed 
minimal toxicity, and 1-year primary patency rate of 76% with the treatment, 
highlighting a significant improvement in AVF matruation.55 There are currently 2 clinical 
trials investigating the use of rapamycin to improve AVF patency. In the ACCESS trial 




delivered locally, via collagen implants, to the vessel wall at the time of AVF creation. In 
the SAVE trial (NCT01595841),57 patients requiring angioplasty to treat AVF failure are 
randomized to receive either rapamycin or placebo. Although these trials are still in 
progress, there are no pre-clinical studies examining the effects of rapamycin on AVF 
patency.  Our data suggests that rapamycin treatment initiated during early maturation 
reduces both SMC and macrophages in the AVF wall (Fig. 1, 7 and 8), contributing to 
improved AVF patency, and support the hypothesis of the ACCESS trial. It is possible that 
differences between our mouse model and human AVF are important; however, the 
mouse model recapitulates human AVF maturation as well as failure rates, suggesting its 
utility in understanding human physiology.42,43 Moreover, mTOR plays a central role in 
regulating metabolic cell processes, including protein and lipid 
synthesis, and autophagy. Chronic mTORC1 inhibition has been associated with muscle 
atrophy, reduced adipogenesis, decreased pancreatic b-cell proliferation and increased 
ketogenesis;58 however, despite these potential side effects associated inhibition of 
mTORC1, the daily 1.4-1.5 µg/cm2 dose of rapamycin used in our study did not affect 
AVF maturation or cause any clinical toxicity. 
Our data show that during early AVF remodeling, rapamycin treatment is 
associated with reduced SMC proliferation and mTORC1 signaling but has no effect on 
proliferation and mTOR signaling in EC (Fig. 1 and 3). These results are consistent with 
our previous work showing that selective knockdown of Akt1 from SMC, but not EC, 
abolishes AVF remodeling,36 and are also in agreement with the long-established role of 




with differentiated SMC contributing to medial wall thickening and resultant venous 
maturation, and dedifferentiated SMC contributing to detrimental neointimal 
hyperplasia.48 It has been suggested that neointimal hyperplasia and the resulting 
thrombosis are the major pathological etiologies of AVF failure.59 Rapamycin most likely 
reduces the inflammation that causes SMC proliferation in AVF, but not SMC 
proliferation directly,60 as shown by its lack of effect on  SMC number when given during 
late remodeling (Fig. 8). Although rapamycin treatment during late AVF remodeling 
reduces mTORC1 signaling in SMC, it does not improve patency or reduce wall 
thickening (Fig. 8). This observation confirms that the increased patency rate with 
rapamycin treatment is due to enhancement of AVF remodeling during the early 
maturation phase when inflammation is most significant (Fig. 1 and 2). The exact 
implications of improved patency with a thinner wall remain to be determined; wall 
thickening is required for AVF maturation, but uncontrolled pathologic remodeling leads 
to AVF failure.3,4 Our data suggests that rapamycin may allow an optimal amount of 
initial outward remodeling, but appears to prevent the excessive wall thickening and 
inward remodeling that can lead to AVF failure.  
AVF creation is associated with local inflammation9 and this inflammatory 
response involves the recruitment of macrophages, lymphocytes, and upregulation of 
cytokines such as IL-6 and TNF-a, all of which are associated with fistula failure.9,50,61 
There is mounting evidence that mTORC1-mediated signaling regulates both adaptive 
and innate immune cell function,62-64 and more specifically, rapamycin attenuates the 




proliferation.65,66 Similarly, we observed that rapamycin treatment is associated with 
reduced number and proliferation of macrophages (Fig. 1) as well as attenuated Akt1-
mTORC1 signaling in macrophages during the early maturation phase (Fig. 3). Our data 
also shows that following macrophage depletion, SMC proliferation decreases. 
Inflammatory cytokines may directly stimulate SMC proliferation and contribute to wall 
thickening,67-69 and Akt activation may promote vascular SMC hypertrophy, leading to 
formation of neointimal hyperplasia.70 Reducing macrophage accumulation decreases 
SMC hyperplasia in vivo, suggesting, as we observe in our AVF model, that macrophages 
play an important role in determining SMC activity during vascular remodeling.67 
Although the exact role of specific macrophage subtypes during AVF maturation 
remains unknown, M1 macrophages accumulate during the early maturation phase of 
venous remodeling, with subsequent increased numbers of M2 macrophages during 
later maturation phases (Fig. 6J).49 Thus, limiting rapamycin delivery to the very early 
phase of maturation to inhibit M1-type macrophage activity appears to result in similar 
or even more improved AVF remodeling (Fig. 8). We have previously shown that CD44 
promotes accumulation of M2-type macrophages, ECM deposition, and inflammation 
resulting in enhanced AVF maturation.15 We have also shown that M2-type macrophage 
function may be an important mechanism in regulating venous remodeling such as 
occurs during vein graft adaptation.54 This study shows that rapamycin attenuates both 
M1 and M2 macrophage activity. While inhibition of pro-inflammatory M1 activity might 
be advantageous in improving AVF patency, complete diminution of macrophage 




the M2-type macrophages (Fig. 6). However, when used to reduce, as opposed to 
deplete, both macrophage phenotypes, rapamycin is associated with improved AVF 
remodeling and patency (Fig. 7). There are mixed reports of rapamycin affecting M2-
type macrophage survival and polarizing the phenotype to an M1-like inflammatory 
response both in vivo and in vitro71 as well as favoring macrophage polarization toward 
an M2 anti-inflammatory response;72 nonetheless, rapamycin treatment is associated 





In conclusion, rapamycin improves AVF patency and early venous remodeling 
while reducing wall thickening and early inflammation. These effects are associated with 
reduced Akt1-mTORC1 signaling in macrophages and SMC during the early maturation 
phase and sustained reduction in SMC during the late maturation phase. Macrophages 
are essential for AVF remodeling and M2 macrophages may have a mechanistic role in 
AVF maturation. The mTORC1 pathway is a key regulator of AVF maturation and its 
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Supplementary Figure 1. Reduced AVF wall thickness, extracellular matrix deposition, SMC and 
macrophages with rapamycin. (A) Bar graphs showing quantification of serum rapamycin 
concentration, *P<0.0001 (t test); BUN, p=0.8506 (t test); creatinine, p=0.3830 (t test); hemoglobin, 
p=0.8502 (t test); platelet, p=0.1116 (t test); white blood cell, p=0.1763 (t test); lymphocyte, p=0.0977 
(t test); neutrophil, p=0.2924 (t test); monocyte, p=0.6748 (t test); weight loss, p=0.5467 (t test) after 
control or rapamycin treatment in mice (day7); n=4-5. (B) Top panel: aortocaval fistula in mice 
treated with control vs rapamycin; middle panel: retroperitoneal tissue dissected to obtain proximal 
control of the aorta and IVC; bottom panel: extracted AVF tied just below the renal veins; arrow 
denotes IVC; scale bar, 1 cm. (C) AVF just below the renal veins in mice treated with control vs 
rapamycin; *: AVF; AO: aorta; scale bar, 100µm. (D) Photomicrographs showing AVF wall thickness in 
mice treated with control vs rapamycin. Scale bar, 25 µm. L, lumen. (E) Line graph showing relative 
AVF arterial diameter in mice treated with control or rapamycin; normalized to day 0; p=0.5(ANOVA). 
n=5-6. (F) Photomicrographs showing dual immunofluorescence (IF) for ICAM-1 (green) and p-eNOS 






Supplementary Figure 1 (continued). (G) Representative IF photomicrographs showing extracellular 
matrix immunoreactivity in control or rapamycin treated groups. Collagen I and III (red) and fibronectin 
(green). (H) Representative IF photomicrographs of ICAM-1 (top row), α-actin (middle row) and CD68+ 
cells (bottom row) in control or rapamycin treated mice AVF. (I) Photomicrographs showing representative 
IF of PCNA (red) merged with ICAM, α-actin or CD68 (green), and DAPI (blue) in AVF of control vs 
rapamycin treated mice (day 3 and 7); L, lumen; scale bar, 25 μm. (J) Photomicrographs showing 
representative IF of cleaved caspase-3 (red) merged with ICAM, α-actin or CD68 (green), and DAPI (blue) in 




Supplementary Figure 2. Reduced M1- and M2-type macrophages with rapamycin. (A) 
Representative photomicrographs showing dual IF for CD68 (red) and iNOS (green, top 
row), TNF-α (green, bottom row). (B) IL10 (green, top row) or CD206 (green, bottom row) 
in AVF after control or rapamycin treatment. (C) Representative IF photomicrographs of 
CD45+ cells. Scale bar, 25 µm. L, lumen. (D) Representative IF photomicrographs of 







Supplementary Figure 3. Reduced Akt1 and mTORC1 but not mTORC2 phosphorylation with 
rapamycin. (A) Representative IF photomicrographs of p-Akt1+ (top), p-mTORC1+ (middle) and 
p-mTORC2+ (bottom) cells in control or rapamycin treated mice AVF; sham, day 3 and day 21. 
Scale bar, 25μm. L, lumen. (B) Representative photomicrographs showing dual IF for ICAM-1 
(green) and p-Akt1 (red, first row) or p-mTORC1 (red, second row) in AVF after control or 
rapamycin treatment; sham, day 3, day 7 and day 21. (C) Bar graphs showing quantification of 
dual IF after control or rapamycin treatment. p-Akt1-α-actin: p=0.2036 (ANOVA); n=4-5. p-
mTORC1-ICAM: p=0.4876 (ANOVA); n=4. (D) Representative photomicrographs showing dual IF 
for α-actin (red) and p-Akt1 (green, top row), α-actin (green) and p-mTORC1 (red, bottom row), 
(E) CD68 (red) and p-Akt1 (green, first row), CD68 (green) p-mTORC1 (red, second row) in AVF 





Supplementary Figure 4. Reduced p70S6K1 and 4EBP1, but not PKCα or SGK1, phosphorylation with 
rapamycin. (A) Photomicrographs of representative IF images of p-p70S6K1+ and p-4EBP1+ cells in control 
or rapamycin treated mice AVF. Scale bar, 25μm. L, lumen. (B) Photomicrographs of representative IF 
images of p-PKCα+ and p-SGK1+ cells in control or rapamycin treated mice AVF. Scale bar, 25μm. L, lumen. 
(C) Representative Western blot showing phosphorylation level of PKCα and SGK1 after control or 
rapamycin treatment. (D) Photomicrographs of representative IF images for α-actin (green) and p-
P70S6K1 (red, top row) or p-4EBP1 (red, bottom row) as well as (E) CD68 (red) and p-P70S6K1 (green, top 






Supplementary Figure 4 (continued). Reduced p70S6K1 and 4EBP1, but not PKCα or SGK1, 
phosphorylation with rapamycin. (F) Microphotographs of representative IF images for α-actin 
(green) and p-PKCα (red, top row) or p-SGK1 (red, bottom row) in AVF after control or rapamycin 
treatment. (G) Bar graphs showing quantification of dual IF after control or rapamycin 
treatment, normalized to sham. p-PKCα-α-actin: p=0.6597 (ANOVA); n=4-5. p-SGK1-α-
actin, p=0.01024 (ANOVA); n=4-5. (H) Photomicrographs of representative IF images for CD68 
(green) and p-PKCα (red, top row) or p-SGK1 (red, bottom row) in AVF after control or rapamycin 
treatment. (I) Bar graphs showing quantification of dual IF after control or rapamycin treatment, 






Supplementary Figure 5. Rapamycin inhibits mTORC1 phosphorylation during venous 
remodeling. (A) Representative photomicrographs showing dual IF for α-actin, CD68 or ICAM 
(green) and HA (red) in AVF after adventitial delivery of control, WT-Akt1, and CA-Akt1; day 21. 
Scale bar, 25μm. L, lumen. (B) Bar graphs showing proportion of HA-ICAM+ to total ICAM+, HA-
α-actin+ to total α-actin+, and HA-CD68+ to total CD68+ cells after adventitial delivery of control, 
WT-Akt1, and CA-Akt1; normalized to control. HA-ICAM: p=0.0012 (ANOVA); Control vs. WT-
Akt1: *, p=0.0136; Control vs. CA-Akt1: **, p=0.0064 (post hoc); n=4. HA-α-actin: p=0.0030 
(ANOVA); Control vs. WT-Akt1: *p<0.0001; Control vs. CA-Akt1: **p<0.0001 (post hoc); n=4. HA-
CD68: p=0.0010 (ANOVA); Control vs. WT-Akt1: *p=0.0006, Control vs. CA-Akt1: **p=0.0004 
(post hoc); n=4. (D) Bar graphs showing quantification of weight loss, p=0.1926 (t test) after 
control or rapamycin treatment in mice (day 21); n=4-5. (C) Line graph showing AVF diameter in 
mice treated with control, WT-Akt1-Ad, CA-Akt1-Ad or CA-Akt1-Ad with rapamycin. p=0.1817 
(ANOVA). n=4–5.  (E) Representative photomicrographs showing dual IF for α-actin (green) and 
p-Akt1 (red, top row) or p-mTORC1 (red, bottom row) as well as (F) CD68 (green) and p-Akt1 
(red, top row) or p-mTORC1 (red, bottom row) in AVF after local delivery of control, WT-Akt1, CA-






Supplementary Figure 6. Macrophage depletion is associated with reduced AVF wall thickness 
and patency. (A) Representative photomicrographs showing CD68+ immunoreactive cells in mice 
treated with control or clodronate. Scale bar, 25μm. L, lumen. Bar graphs showing number of 
CD68+ cells in AVF after control or clodronate treatment. *p<0.0001 (t test). n=5. (B) 
Representative photomicrographs showing dual IF for CD68 (red) and iNOS (green, top row), 
TNF-a (green, second row), IL-10 (green, third row) or CD206 (green, bottom row) in AVF after 
control or rapamycin treatment; day 7. Scale bar, 25 μm. L, lumen. Bar graphs showing 
quantification of dual IF after control or clodronate treatment (day 7). CD68-iNOS: p=0.01351 (t 







Supplementary Figure 7. Rapamycin treatment is associated with reduced AVF wall thickness 
but increased AVF patency. (A) Bar graphs showing quantification of weight change, p=0.1977 (t 
test) after control or rapamycin treatment in mice (day 42); n=12-13. (B) Technical success rate 
of AVF creation in rapamycin treated group (77.8%; 14/18) compared to control (76.5%; 13/17); 
P=0.9871 (chi-square).  (C) Line graph showing AVF patency rate in mice treated with IP 
rapamycin or adventitial delivery of a single dose of rapamycin via pluronic gel. *P = 0.9027 (Log-
rank), n=6-7 in each arm. 
 
